Flow Cytometry:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Expressing:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Control:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Marker:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
In Vivo:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Injection:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Growth Assay:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Viability Assay:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Enzyme-linked Immunosorbent Assay:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Detection Assay:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Western Blot:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Software:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Transduction:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Apoptosis Assay:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Two Tailed Test:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
MANN-WHITNEY:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Immunohistochemistry:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
Biomarker Discovery:Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins
Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.. For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.For blocking experiments, specific blocking reagents (Biolegend), including anti-MICA/B, anti-ICAM-1, anti-NKG2D antibody, recombinant NKG2D, and an isotype-matched control antibody (mouse IgG1κ from Invitrogen) were used at a final concentration of 20 μg/mL.
Article Title: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Article Snippet: All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.All cell lines underwent DNA authentication using Cell IDTM System (Promega) and mycoplasma testing (Lonza) before the described experiments.. Fulvestrant (ICI 182,780, Tocris) was dissolved in ethanol 96%, AKTi capivasertib (HY-15431, MedchemExpress), CDK4/6i ribociclib succinate hydrate (HY-15777C, MedchemExpress), CDK4/6i abemaciclib (HY-16297A, MedchemExpress), and dual PI3K/mTORi gedatolisib (#HY-10681, MedchemExpress) were dissolved in DMSO (Sigma-Aldrich) and CDK4/6i palbociclib isothiocyanate (HY-A0065, MedchemExpress) was dissolved in water.. The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.The concentrations of CDK4/6i, AKTi, and dual PI3K/mTORi to be used for in vitro experiments were determined based on the IC for each cell line model.
|
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
